Itäinen Pitkäkatu 4 B
8 articles with Forendo Pharma
Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219
Forendo Pharma announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.
Turku, Finland, July 19th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo.
Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis
Forendo Pharma today announces that it has successfully completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis.
Forendo Commences Phase Ia Study for FOR-6219 for Endometriosis
Vesalius Biocapital III Partners invests in Karolinska Development's portfolio company Forendo Pharma
Karolinska Development's portfolio company Forendo Pharma announces today that Vesalius Biocapital III Partners (Vesalius) joins Forendo Pharma's existing international investor syndicate.
Forendo Pharma Nominates World Class Scientific Advisory Board And Elects Professor Linda Giudice As The Chairperson